Adding pembrolizumab to THP improved pCR rates in patients with HER2-positive breast cancer in the phase 2 NeoHIP trial.

T-DXd outperformed physician’s choice of chemotherapy regardless of patients’ disease burden or time to progression on prior therapy.

Paclitaxel-based and nab-paclitaxel-based chemotherapy produced similar 5-year outcomes in patients with high-risk, HR+, HER2- early breast cancer.

Omitting axillary SLNB does not impact outcomes in patients with early invasive breast cancer undergoing breast-conserving surgery, data suggest.

Rucaparib Maintenance Improves Long-Term Outcomes in Ovarian Cancer Rucaparib maintenance after first-line chemotherapy and ...

Adding tafasitamab to treatment with lenalidomide and rituximab improved progression-free survival in patients with relapsed or refractory follicular lymphoma.

Adding pyrotinib to trastuzumab and docetaxel prolonged progression-free survival in patients with HER2-positive metastatic breast cancer.

Palbociclib plus ET improved outcomes over chemotherapy ± ET maintenance in patients with high-risk, HR+, HER2- metastatic breast cancer.

Fedratinib can reduce symptoms and spleen volume in patients with myelodysplastic syndrome (MDS) or myeloproliferative neoplasms (MPNs), according to research presented at the ASH Annual Meeting 2024.

The all-oral combination of revumenib, venetoclax, and ASTX727 demonstrated efficacy in relapsed/refractory AML.

Lenalidomide improved upon the efficacy of durvalumab in patients with refractory or advanced CTCL in a phase 1/2 trial.

This page includes links to articles highlighting the top skin cancer research published on Cancer Therapy Advisor in 2024.